GLP-1R knockout mice (GLP-1R KO, Shanghai Model Organisms, based on C57BL/6N) were generated using CRISPR/Cas9 technology, which causes Glp1r gene protein reading frame shift and loss of function by using non-homologous recombination repair to introduce mutations
Analysis of serious weight gain in patients using alectinib for ALK positive lung cancer, semaglutide a potential treatment for serious weight gain from ALK tyrosine kinase inhibitors
Additionally, their associated benefits of reduced blood glucose content (glycemia), kidney disease, fatty liver, and improved cardiovascular functioning make them a viable alternative to conventional bariatric surgery and underscore significant medical advances in combatting obesity
There are a number of these medications currently available, some of which include: Semaglutide injection (Ozempic) Semaglutide injection (Wegovy) Semaglutide tablets (Rybelsus) Dulaglutide (Trulicity) Exenatide (Byetta) Exenatide extended-release (Bydureon) Liraglutide (Victoza) Lixisenatide (Adlyxin) Tirzepatide injection (Mounjaro) Source [1] Global GLP-1 receptor agonist market In 2024, the global GLP-1 receptor agonist market size was valued at an estimated USD 53.46 billion and is projected to reach USD 156.71 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 17.46% between 2025 and 2030
